As­traZeneca's Calquence nabs an­oth­er win against Im­bru­vi­ca, but Eli Lil­ly is on its heels

Three years af­ter first launch­ing Calquence as a sec­ond gen­er­a­tion BTK in­hibitor, As­traZeneca con­tin­ues to tout new da­ta to com­pete with J&J and Ab­b­Vie’s first …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER